Prostate Cancer

“The 3 major barriers we face [are] training, equipment, and reimbursement,” says Matthew A. Allaway, MD.

“These results may help guide policy making, developing quality indicators, and developing targeted continued education for physician and patients embarking on active surveillance to establish realistic expectations,” said Antonio Finelli, MD.

Using stereotactic body radiotherapy to reduce the number of treatment sessions with fewer, more intense doses did not lead to an increase in gastrointestinal or genitourinary acute toxicity.

The FDA approved the ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate earlier this year for the treatment of patients with advanced prostate cancer.

Risk factors Dr.Zhang highlights include site of metastases, PSA response, and metastases burden.

“The MRI/ultrasound-guided transperineal approach allows easy access to anterior prostate tumors,” says Marc A. Bjurlin, DO, MSc, FACOS, in this video.

"The major shift for many urologists over the past 10 years has undoubtedly been the understanding of how to treat advanced prostate cancer," writes Raoul S. Concepcion, MD, FACS.

“New and different drugs indicated at different points in the treatment cycle have been the biggest change," says 1 urologist.

In this interview, Marc A. Bjurlin, DO, MSc, FACOS, explains the advantages of prostate MRI, in which patients it is best used, and whether it can be considered the gold standard for prostate cancer detection

Daniel C. Danila, MD, discusses choosing among the androgen receptor inhibitors darolutamide, enzalutamide, and apalutamide when treating patients with castration-resistant prostate cancer.

Results from the phase 2 TALAPRO-1 study published in the Lancet Oncology show favorable antitumor activity with talazoparib in heavily pretreated patients with metastatic castration-resistant prostate cancer and DDR-HRR gene alterations.

Ventana MMR RxDx Panel is a qualitative immunohistochemistry test that assesses a panel of MMR proteins to help guide clinicians in their treatment decisions.

Combining the Stockholm3 blood test with MRI-guided prostate biopsy reduced the number of MRIs performed and lowered overdetection, while not sacrificing the capacity to identify clinically significant tumors, according to findings from the STHLM3-MRI study.

Jingsong Zhang, MD, PhD, discusses how the site of metastases impacts his approach to treatment selection for patients with metastatic castration-resistant prostate cancer.

“It is always important to think about how the imaging and the way we read the imaging can improve, right and be used in a way that makes the most sense for the decision at hand,” says Stella K. Kang, MD, in this podcast.

Susan F. Slovin, MD, PhD, discusses the plethora of available treatment options and factors affecting treatment selection for patients with metastatic castration-sensitive prostate cancer.

"It is apparent from the results of these 2 studies that neither the higher-dose RT nor early RT after RP provide sufficient oncological benefits to justify the adverse impact on functional outcomes and HRQOL," writes Badar M. Mian, MD.

The FDA has officially released its finalized recommendation for the use of metastases-free survival as an end point in clinical trials evaluating treatments for patients with nonmetastatic castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, summarizes the key points urologists need to know about how PARP inhibitors are currently used in the prostate cancer paradigm.

“I would say, over the last several years, [MRI has] really become a popular thing to do prebiopsy,” says Ketan K. Badani, MD.

Among patients treated through the Veteran’s Health Administration, Black men with prostate cancer were less likely to choose or be offered the most beneficial treatment options.

“One of the toughest parts about having a discussion with a patient about low-risk or early-stage prostate cancer…is actually deciding what might be best for that individual patient,” says Ketan K. Badani, MD.

“I think as technology evolves, we as urologists need to continue to evolve and make changes to our practice,” says Kevin T. Keating, DO.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.